Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This article appeared on The Mackinac Center for Public Policy on June 12, 2019.

In Canada, Australia, the United Kingdom and elsewhere, government-run health care systems use “quality-adjusted life years” to help determine what medical procedures and drugs are available for patients. In theory, this prevents people from getting unnecessary treatment and helps prioritize patient care.

But in practice, it boils down to rationing, carried out by government bureaucrats. Pushed out of the equation are two key participants in medical care: doctors and patients. In Britain, for instance, this type of rationing has led to cancer patients having severely limited access to new treatments that are widely available in other countries. And the quality of life measure may be coming to the United States.

Dr. William Smith wrote a report critical of the QALY standard, questioning the extent that governments gets involved in judgments on the value of human life. At this event, he will discuss quality-life measurements, compare the difference between the government and private insurance when determining treatment and talk about the push for rationing by federal and state governments.

 

Get Updates On Our Work to Protect Patients and Innovation!

Recent Research:

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

ICER Proves Its Lack of Business Acumen, Again

/
A recent Institute for Clinical and Economic Review (ICER) “Report on Unsupported Price Increases,” concluded that: “Among the top drugs with price increases in 2019…ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known.”  The impression left by the report is that drug companies arbitrarily raise prices without good reason.  As with so many ICER products, the study is misleading and demonstrates a profound lack of business acumen.

Report: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework

/
This op-ed appeared in ICERWatch on June 26, 2019. The Institute…

Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

/
This article appeared on The Mackinac Center for Public Policy…

Issue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology

/
This article by Chris Rochester appeared in The MacIver Institute…